News
The development serological markers for detecting recent Plasmodium vivax infection has been successful
The international research group comprising of Proteo-Science Center, Ehime University’s Dr. Eizo Takashima, Dr. Masayuki Morita, and Dr. Takafumi Tsuboi along with CellFree Sciences Co., Ltd.’s Dr. Matthias Harbers succeeded in developing a serological diagnostic marker that can identify those with dormant liver stage infections, which are the causes of Plasmodium vivax recurrences.
This result has been achieved by an international joint research project with the main members including Proteo-Science Center, Ehime University, CellFree Sciences Co., Ltd., The Walter and Eliza Hall Institute of Medical Research (WEHI), Pasteur Institute, and Foundation for Innovative New Diagnostics (FIND).
Further, this project was started with assistance from the Global Health Innovative Technology Fund (GHIT Fund) between October 2015 and March 2017.
This research result allows the diagnosis of Plasmodium vivax’s dormant liver stage parasites which has been a difficult challenge in eliminating malaria, for the first time in the world. It can be seen as an important result to safely and effectively promote the treatment.
The paper regarding this research result has been published on the May 12th (Tues.) 2020 issue of the Nature Medicine.
Development and validation of serological markers for detecting recent Plasmodium vivax infection
Contributed to support the development of monoclonal antibody detection of the novel coronavirus
The joint research group, which primarily studies under Dr. Akihide Ryo for Yokohama City University, has succeeded in the development of monoclonal antibodies to specifically detect novel coronavirus (SARS-CoV-2) antigens, and has utilized our company's Wheat Germ Cell-free Protein Expression System in the production of the antigen.
For further details, Please click here.
Ehime University et al. receive research grant for development of malaria vaccines
The Proteo-Science Center (PROS), Ehime University et al. research group, which is the strategic technical partner of our company, has received a research grant totaling approximately 600 million yen for research to develop transmission-blocking vaccines for malaria elimination from Global Health Innovative Technology Fund (GHIT Fund).
Up to now we have supplied wheat germ extract to support malaria research through wheat germ cell-free protein expression system and it is our hope this malaria vaccine development will be one more step of progress in the battle to malaria elimination.
Contributed to novel coronavirus antibody detection technology
Our company's Wheat Germ Cell-free Protein Expression System was used to produce the antigen necessary for antibody detection in the technology developed by Dr. Akihide Ryo of Yokohama City University that is used to detect antiviral antibodies against novel coronavirus.
We in collaboration with Ehime University have developed a new technology to conduct a genome wide evaluation of the specificity of antibodies that can bind to human proteins.
The groups from CellFree Sciences Co., Ltd. (Ryo Morishita, R&D manager) and Proteo-Science Center, Ehime University (Professor Tatsuya Sawasaki) have successfully developed a new technology that identifies proteins for binding to target antibodies. Using about 20,000 human proteins this technology is best suited for veriflying the specificity of antibodies against human proteins.
The new technology utilizes a protein bead array technology developed by CellFree Sciences Co., Ltd. named “CF-PA2Vtech”. The potential of the new method was demonstrated by verifying the specific binding of a commercial anti-PD-1 antibody, where the data demonstrate its binding to several proteins having related linear epitopes.
The results from the research were published by Morishita et al. in the December 18, 2019 issue of Scientific Reports:
CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins
We will be at The 10th Conference on Biomolecular Screenology.
CellFree Sciences will be at The 10th Conference on Biomolecular Screenology at Tower Hall Funabori, Tokyo, Japan from November 22, 2019.
■Poster
[Title of Abstract]
Antibody validation using a wheat germ cell-free based human protein array "CF-PA2Vtech".
[Poster No.]
P4
[Date]
November 22 (Fri.)
[Discussion Time]
14：20-14：50
We will be at The 48th Annual Meeting of the Japanese Society for Immunology.
CellFree Sciences will be at the 48th Annual Meeting of the Japanese Society for Immunology at Act City Hamamatsu, Hamamatsu, Japan from December 11 to 13, 2019.
■Poster
[Title of Abstract]
Validation technology of antibody specificity using a protein array covering about 80% of the human proteome
[Poster No.]
1-F-WS4-14-P
[Date]
December 11 (Wed.)
[Discussion Time]
17:35-18:20
We are looking forward to welcome you.
We will be at The 42nd Annual Meeting of the Molecular Biology Society of Japan.
CellFree Sciences will be at The 42nd Annual Meeting of the Molecular Biology Society of Japan at Marine Messe Fukuoka, Fukuoka, Japan from December 3 to 6, 2019.
■Poster
[Title of Abstract]
Evaluation of anti-PD-1 antibody by validation technology of antibody specificity using a cell-free based human protein array
[Poster No.]
2P-0645
[Date]
December 4 (Wed.)
[Discussion Time]
Free discussion：13:30～14:00
■Booth
[Booth No.]
6
[Schedule]
December 3 (Tue.) 9:30-17:00
December 4 (Wed.) 9:30-17:00
December 5 (Thu.) 9:30-17:00
December 6 (Fri.) 9:30-12:45
We are looking forward to welcome you to our booth and to provide you with more information on the use of our protein expression products and services including genome-wide protein expression studies, expression of membrane proteins, GPCR and proteins for mass spectrometry.
We will be at The 67th Annual Meeting of the Japanese Society for Virology.
CellFree Sciences will be at The 67th Annual Meeting of the Japanese Society for Virology at Tower Hall Funabori, Tokyo, Japan from October 29 to 31, 2019.
Please visit us at Booth Location : 5
We are looking forward to welcome you to our booth and to provide you with more information on the use of our protein expression products and services including genome-wide protein expression studies, expression of membrane proteins, GPCR and proteins for mass spectrometry.
Our company was featured on NHK news.
The research results of "Proteo-Science Center" at Ehime University were presented at the 17th Protein Island Matsuyama International Symposium held on August 11th. Our company was featured on NHK news on the same day.
For further details, Please click here.
